Creating a new treatment to help the gut after radiation exposure
Development of a Novel Therapeutic for Mitigating Radiation-Induced Microbiome Dysbiosis and Acute Gastrointestinal Syndrome
This study is testing a new treatment called MIIST305 to help protect your gut from damage caused by high doses of radiation, like what might happen in a nuclear event, by promoting healing and reducing inflammation.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11012255 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic agent, MIIST305, aimed at mitigating the harmful effects of radiation on the gastrointestinal (GI) tract. It targets microbiome dysbiosis and acute gastrointestinal syndrome that can occur after high-dose radiation exposure, such as from a nuclear event. The approach involves administering the drug after radiation exposure to reduce cell death, inflammation, and promote tissue regeneration. The research utilizes advanced gene sequencing techniques to understand the microbiome changes and the therapeutic effects of MIIST305.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to high doses of radiation, particularly in scenarios involving mass casualty events.
Not a fit: Patients who have not been exposed to radiation or those with pre-existing severe gastrointestinal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a critical treatment option for patients suffering from radiation-induced gastrointestinal injuries.
How similar studies have performed: Preliminary studies have shown promising results with similar therapeutic approaches in animal models, indicating potential for success in human applications.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Broustas, Constantinos G. — Columbia University Health Sciences
- Study coordinator: Broustas, Constantinos G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.